New Breast Cancer Clinical Trial – Genentech - Trastuzumab-DM1
Posted Nov 11 2008 1:12pm
The trial is for women who have the HER2 gene and have already received treatments, details listed below. BD
The Barbara Ann Karmanos Institute is looking for women with HER2 positive metastatic breast cancer to participate in a clinical trial. The Phase II trial at Karmanos is part of an international study to further test a new drug Trastuzumab-DM1, in development by Genentech. The trial will be under the direction of Patricia LoRusso, D.O., Karmanos director of the Phase I Clinical Trials Program and professor of internal medicine at Wayne State University. "We are actively recruiting women to join this study and encourage them to call us for additional information," said Dr. LoRusso. She stated that eligible patients must have HER2 positive metastatic breast cancer, tumors measurable by radiographic evaluation, progressed on Herceptin, Tykerb and Xeloda, and show no current evidence of brain cancer.